HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luana Calabrò Selected Research

tremelimumab

1/2021Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
8/2020Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy.
2/2020Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
1/2018Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
1/2017Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
4/2015Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
1/2015CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
1/2014Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
10/2013Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
10/2010Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luana Calabrò Research Topics

Disease

31Neoplasms (Cancer)
06/2022 - 05/2002
20Melanoma (Melanoma, Malignant)
07/2021 - 02/2002
12Mesothelioma
01/2022 - 01/2015
10Malignant Mesothelioma
01/2022 - 10/2013
8Disease Progression
01/2022 - 02/2003
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2021 - 11/2018
4COVID-19
01/2022 - 01/2020
4Testicular Neoplasms (Testicular Cancer)
12/2021 - 02/2005
3Pneumonia (Pneumonitis)
01/2022 - 11/2018
3Hematologic Neoplasms (Hematological Malignancy)
10/2005 - 05/2002
2Neutropenia
01/2022 - 11/2018
2Brain Neoplasms (Brain Tumor)
01/2021 - 10/2019
2Hypophysitis
08/2020 - 12/2017
2Diarrhea
11/2018 - 01/2012
2Infections
11/2018 - 01/2017
2Respiratory Insufficiency (Respiratory Failure)
11/2018 - 01/2017
2Heart Failure
11/2018 - 01/2017
2Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2004 - 05/2002
2Leukemia
05/2002 - 02/2002
1Neuroendocrine Tumors (Neuroendocrine Tumor)
06/2022
1Renal Insufficiency (Renal Failure)
01/2022
1Liver Failure
01/2022
1Atrial Fibrillation
01/2022
1Sepsis (Septicemia)
01/2022
1Arthrogryposis renal dysfunction cholestasis syndrome
01/2022
1Glioblastoma (Glioblastoma Multiforme)
07/2021
1Diabetes Insipidus
08/2020
1Neurogenic Diabetes Insipidus (Central Diabetes Insipidus)
08/2020
1Lung Neoplasms (Lung Cancer)
01/2020
1Brain Diseases (Brain Disorder)
10/2019
1Dehydration (Water Stress)
11/2018
1Fever (Fevers)
11/2018
1Inflammation (Inflammations)
11/2018
1Myocarditis (Carditis)
11/2018
1Septic Shock (Toxic Shock Syndrome)
11/2018
1Interstitial Lung Diseases (Interstitial Lung Disease)
11/2018
1Acute Kidney Injury (Acute Renal Failure)
11/2018
1Febrile Neutropenia
11/2018
1Prostatic Neoplasms (Prostate Cancer)
12/2017
1Myocardial Infarction
01/2017
1Colitis
01/2017
1Thrombocytopenia 1
01/2012

Drug/Important Bio-Agent (IBA)

13Monoclonal AntibodiesIBA
10/2019 - 02/2002
10IpilimumabIBA
01/2021 - 08/2009
10tremelimumabIBA
01/2021 - 10/2010
10Immune Checkpoint InhibitorsIBA
08/2020 - 01/2014
7PlatinumIBA
01/2022 - 10/2013
7AntigensIBA
12/2021 - 02/2005
7AntibodiesIBA
11/2018 - 10/2010
5NivolumabIBA
01/2021 - 11/2018
5durvalumabIBA
01/2021 - 01/2018
5Proteins (Proteins, Gene)FDA Link
02/2020 - 02/2002
4Biomarkers (Surrogate Marker)IBA
01/2021 - 06/2013
3Docetaxel (Taxotere)FDA Link
01/2021 - 11/2018
3Messenger RNA (mRNA)IBA
10/2010 - 02/2002
2avelumabIBA
01/2021 - 11/2018
2B7-H1 AntigenIBA
02/2020 - 11/2018
2LigandsIBA
10/2019 - 01/2017
2DNA (Deoxyribonucleic Acid)IBA
08/2007 - 10/2005
1Sirolimus (Rapamycin)FDA Link
06/2022
1EverolimusFDA Link
06/2022
1MesothelinIBA
01/2022
1mRNA VaccinesIBA
01/2022
1VaccinesIBA
01/2022
1anetumab ravtansineIBA
01/2022
1Vinorelbine (Navelbine)FDA LinkGeneric
01/2022
1Pemetrexed (MTA)FDA Link
01/2022
1Bevacizumab (Avastin)FDA Link
01/2022
1Immunoglobulin G (IgG)IBA
01/2022
1Neutralizing AntibodiesIBA
01/2022
1guadecitabineIBA
12/2021
1tazemetostatIBA
12/2021
1Pharmaceutical PreparationsIBA
10/2021
1pembrolizumabIBA
01/2021
1fotemustine (Muphoran)IBA
01/2021
1AutoantigensIBA
08/2020
1Adrenocorticotropic Hormone (ACTH)FDA Link
08/2020
1Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric
08/2020
1Apoptosis Regulatory ProteinsIBA
02/2020
1Immunoglobulins (Immunoglobulin)IBA
10/2019
1ErbB Receptors (EGF Receptor)IBA
11/2018
1Anaplastic Lymphoma KinaseIBA
11/2018
1Immune Checkpoint ProteinsIBA
11/2018
1Transaminases (Aminotransferases)IBA
11/2018
1Lipase (Acid Lipase)FDA Link
11/2018
1ThymalfasinIBA
01/2018
17- iodo- 8- hydroxy- 3- methyl- 1- (4- azidophenyl)- 2,3,4,5- tetrahydro- 1H- 3- benzazepineIBA
01/2018
1micaIBA
01/2017
1CTLA-4 AntigenIBA
01/2017
1Therapeutic UsesIBA
10/2012
1Interferon-alpha (Interferon Alfa)IBA
10/2012
1Dacarbazine (DIC)FDA LinkGeneric
10/2012
1ThymosinIBA
10/2012

Therapy/Procedure

16Therapeutics
01/2022 - 08/2009
13Immunotherapy
12/2021 - 05/2010
8Drug Therapy (Chemotherapy)
01/2022 - 08/2009
3Biological Therapy
07/2021 - 01/2017
2Retreatment
01/2021 - 01/2014
1Aftercare (After-Treatment)
11/2018
1EAP protocol
10/2013